ReviewPharmacotherapy2025

Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review.

Candice L Garwood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.